1869 Participants Needed

Tozorakimab for COPD

(PROSPERO Trial)

Recruiting at 299 trial locations
AC
Overseen ByAstraZeneca Clinical Study Information Center
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This trial is testing Tozorakimab, a medication that aims to reduce lung inflammation, in adults aged 40 and older with COPD. The goal is to see if it can help them breathe better and have fewer symptoms.

Do I have to stop taking my current medications for the trial?

The trial does not specify if you need to stop taking your current medications, but it does mention that chronic use of immunosuppressive medications is not allowed. It's best to discuss your specific medications with the study team.

What data supports the effectiveness of the drug Tozorakimab for COPD?

The research suggests that monoclonal antibodies (mABs), like those targeting inflammation in COPD, can moderately reduce the risk of exacerbations (flare-ups) in COPD patients. While specific data on Tozorakimab is not provided, similar treatments like mepolizumab have shown benefits in reducing exacerbations in patients with high eosinophil counts, indicating potential effectiveness for Tozorakimab in similar patient groups.12345

What makes the drug Tozorakimab unique for treating COPD?

Tozorakimab (MEDI-3506) is unique for treating COPD because it targets the interleukin-6 (IL-6) pathway, which is involved in inflammation, potentially offering a novel approach compared to standard COPD treatments that primarily focus on bronchodilation and symptom relief.678910

Eligibility Criteria

This trial is for adults with symptomatic COPD who've completed the OBERON or TITANIA studies without early discontinuation. They must have taken their last dose within 12 weeks and agree to continue using contraception. Excluded are those with significant health issues, involvement in study planning, inability to follow study requirements, known allergies to trial drugs, or use of certain immunosuppressives.

Inclusion Criteria

I am able to understand and sign the consent form.
Participants who have completed the treatment period and have not been prematurely discontinued from IP in the predecessor studies
Women who could become pregnant must have a negative urine pregnancy test at the first visit.
See 2 more

Exclusion Criteria

I regularly take or will need to take medication that affects my immune system.
I can follow all study requirements and procedures.
Any clinically significant disorder or abnormal findings (clinical, laboratory, instrumental, etc) or major physical and/or cognitive impairment - which, in the opinion of the Investigator, may put the participant at risk because of his/her participation in the study or impact the interpretation of the study results, or otherwise make the participation of the participant inappropriate
See 5 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Tozorakimab or placebo subcutaneously to evaluate long-term efficacy and safety in COPD

104 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Open-label extension (optional)

Participants may opt into continuation of treatment long-term

Long-term

Treatment Details

Interventions

  • Tozorakimab
Trial OverviewThe trial tests Tozorakimab's long-term safety and effectiveness against a placebo in managing COPD symptoms. It's a phase 3 extension from previous studies (OBERON/TITANIA), maintaining a double-blind approach where neither participants nor researchers know who receives the actual drug versus placebo.
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Tozorakimab Dose 2Experimental Treatment1 Intervention
Injection subcutaneously Tozorakimab via pre-filled syringe.
Group II: Tozorakimab Dose 1Experimental Treatment1 Intervention
Injection subcutaneously Tozorakimab via pre-filled syringe.
Group III: PlaceboPlacebo Group1 Intervention
Injection subcutaneously with equivalent volume to Tozorakimab via pre-filled syringe.

Find a Clinic Near You

Who Is Running the Clinical Trial?

AstraZeneca

Lead Sponsor

Trials
4,491
Recruited
290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Findings from Research

Monoclonal antibody (mAB) therapies have a moderate effect on reducing the risk of exacerbations in chronic obstructive pulmonary disease (COPD), but they do not significantly improve lung function (FEV1) or quality of life (SGRQ).
In eosinophilic COPD patients, the IL-5 antagonist mepolizumab was found to reduce exacerbation risk, while benralizumab showed effectiveness in improving both lung function and quality of life, highlighting the potential of targeting IL-5 pathways in specific patient populations.
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis.Rogliani, P., Matera, MG., Puxeddu, E., et al.[2019]
In a meta-analysis of 1136 patients from the METREX and METREO trials, mepolizumab significantly reduced the annual rate of moderate to severe exacerbations in COPD patients with elevated blood eosinophil counts by 18% compared to placebo.
The study found that higher blood eosinophil counts were associated with greater efficacy of mepolizumab, suggesting that patients with eosinophil counts of ≥150 cells/µL at screening or ≥300 cells/µL in the prior year are more likely to benefit from this treatment.
Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO.Pavord, ID., Chapman, KR., Bafadhel, M., et al.[2021]
In a study involving 66 COPD patients and 15 healthy controls, it was found that COPD serum significantly increased pro-inflammatory markers like CCL5 and TNF-α while decreasing the anti-inflammatory marker IL-10, indicating a strong pro-inflammatory effect in COPD.
The p38 inhibitor SB203580 was able to suppress inflammation by reducing CCL5 and TNF-α levels and increasing IL-10 production, but its effectiveness was limited in COPD patients, suggesting that there are other inflammatory mechanisms at play that do not involve p38 signaling.
In vitro modeling of COPD inflammation and limitation of p38 inhibitor - SB203580.Meng, A., Zhang, X., Wu, S., et al.[2018]

References

Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. [2019]
Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. [2021]
In vitro modeling of COPD inflammation and limitation of p38 inhibitor - SB203580. [2018]
Precision medicine in COPD: review of mepolizumab for eosinophilic COPD. [2020]
Current Perspectives on Biological Therapy for COPD. [2023]
Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial. [2020]
Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials. [2020]
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases. [2023]
Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells. [2020]
Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. [2022]